A Low Serum Iron Level Is a Predictor of Poor Outcome in Hemodialysis Patients

American Journal of Kidney Diseases

Volumn 43, Issue 4, 2004, Pages 671-684

  Kalantar Zadeh, Kamyar ^a   McAllister, Charles J ^b   Lehn, Robert S ^b   Liu, Enwu ^b   Kopple, Joel D ^b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b NONE

Author keywords

Erythropoietin (EPO); Hemodialysis (HD); Hospitalization; Mortality; Reverse epidemiology; Serum iron; Transferrin saturation ratio

Indexed keywords

C REACTIVE PROTEIN; ERYTHROPOIETIN; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; FERROUS GLUCONATE; IRON; IRON DEXTRAN;

ADULT; AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; FEMALE; HEMODIALYSIS; HOSPITALIZATION; HUMAN; IRON BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; POISSON DISTRIBUTION; UNITED STATES;

EID: 1642422883     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2003.12.029     Document Type: Article

References (39)

1. US Renal Data System: USRDS 2003 Annual Data Report. The National Institutes of Health, Bethesda, MD, National Institute of Diabetes and Digestive and Kidney Diseases, 2003
2. Madore F, Lowrie EG, Brugnara C, et al: Anemia in hemodialysis patients: Variables affecting this outcome predictor. J Am Soc Nephrol 8:1921-1929, 1997
3. Triolo G, Canavese C, Di Giulio S: Reasons for producing guidelines on anemia of chronic renal failure: Dialysis Outcome Quality Initiative of the National Kidney Foundation. Int J Artif Organs 21:751-756, 1998
4. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 28:53-61, 1996
5. Moreno F, Aracil FJ, Perez R, Valderrabano F: Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia with erythropoietin. Am J Kidney Dis 27:548-556, 1996
6. Auer J, Simon G, Stevens J, et al: Quality of life improvements in CAPD patients treated with subcutaneously administered erythropoietin for anemia. Perit Dial Int 12:40-42, 1992
7. Kalantar-Zadeh K, McAllister CJ, Lehn RS, Lee GH, Nissenson AR, Kopple JD: Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis 42:761-773, 2003
8. Kalantar-Zadeh K, Block G, McAllister CJ, Humphreys MH, Kopple JD: Appetite and inflammation, nutrition, anemia and clinical outcome in hemodialysis patients. Am J Clin Nutr 2004 (in press)
9. Kalantar-Zadeh K, Block G, McAllister C, Kopple JD: A low, rather than a high, plasma homocysteine is a marker of poor outcome in dialysis patients. J Am Soc Nephrol 2004 (in press)
10. Kalantar-Zadeh K, Kopple J, Humphreys M, Block G: Comparing outcome predictability of markers of malnutrition-inflammation complex syndrome in hemodialysis patients. Nephrol Dial Transplant 2004 (in press)
11. Fried L, Bernardini J, Piraino B: Charlson comorbidity index as a predictor of outcomes in incident peritoneal dialysis patients. Am J Kidney Dis 37:337-342, 2001
12. Beddhu S, Bruns FJ, Saul M, Seddon P, Zeidel ML: A simple comorbidity scale predicts clinical outcomes and costs in dialysis patients. Am J Med 108:609-613, 2000
13. Kalantar-Zadeh K, Kopple JD, Block G, Humphreys MH: A malnutrition-inflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients. Am J Kidney Dis 38:1251-1263, 2001
14. Bergstrom J, Alvestrand A, Lindholm B, Tranaeus A: Relationship between Kt/V and protein catabolic rate (PCR) is different in continuous peritoneal dialysis and hemodialysis patients. J Am Soc Nephrol 2:358, 1991
15. Kalantar-Zadeh K, Supasyndh O, Lehn RS, McAllister CJ, Kopple JD: Normalized protein nitrogen appearance is correlated with hospitalization and mortality in hemodialysis patients with Kt/V greater than 1.20. J Ren Nutr 13:15-25, 2003
16. Beerenhout C, Bekers O, Kooman JP, van der Sande FM, Leunissen KM: A comparison between the soluble transferrin receptor, transferrin saturation and serum ferritin as markers of iron state in hemodialysis patients. Nephron 92:32-35, 2002
17. Kalantar-Zadeh K, Kleiner M, Dunne E, et al: Total iron-binding capacity-estimated transferrin correlates with the nutritional subjective global assessment in hemodialysis patients. Am J Kidney Dis 31:263-272, 1998
18. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347:1557-1565, 2002
19. Erbagci AB, Tarakcioglu M, Aksoy M, et al: Diagnostic value of CRP and Lp(a) in coronary heart disease. Acta Cardiol 57:197-204, 2002
20. National Kidney Foundation: K/DOQI Clinical Practice Guidelines: Anemia of Chronic Kidney Disease. Am J Kidney Dis 37:S182-S238, 2001 (suppl 1)
21. Kalantar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD: Malnutrition-inflammation complex syndrome in dialysis patients: Causes and consequences. Am J Kidney Dis 42:864-881, 2003
22. Kalantar-Zadeh K, Don BR, Rodriguez RA, Humphreys MH: Serum ferritin is a marker of morbidity and mortality in hemodialysis patients. Am J Kidney Dis 37:564-572, 2001
23. Kalantar-Zadeh K, Luft FC: Diagnosis of iron deficiency in ESRD patients. Am J Kidney Dis 30:455-456, 1997
24. Neyra NR, Hakim RM, Shyr Y, Ikizler TA: Serum transferrin and serum prealbumin are early predictors of serum albumin in chronic hemodialysis patients. J Ren Nutr 10:184-190, 2000
25. Kalantar-Zadeh K, Rodriguez R, Humphreys M: Association between serum ferritin and measures of inflammation, nutrition, and iron in hemodialysis patients. Nephrol Dial Transplant 2004 (in press)
26. Kalantar-Zadeh K, Hoffken B, Wunsch H, Fink H, Kleiner M, Luft FC: Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era. Am J Kidney Dis 26:292-299, 1995
27. Clinical Laboratory Medicine (ed 6). St Louis, MO, Mosby-Year Book, 1995
28. Alvarez-Hernandez X, Liceaga J, McKay IC, Brock JH: Induction of hypoferremia and modulation of macrophage iron metabolism by tumor necrosis factor. Lab Invest 61:319-322, 1989
29. Letendre ED: Iron metabolism during infection and neoplasia. Cancer Metastasis Rev 6:41-53, 1987
30. Zager RA, Johnson AC, Hanson SY, Wasse H: Parenteral iron formulations: A comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 40:90-103, 2002
31. Drueke T, Witko-Sarsat V, Massy Z, et al: Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 106:2212-2217, 2002
32. Feldman HI, Santanna J, Guo W, et al: Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol 13:734-744, 2002
33. Eschbach JW, Adamson JW: Iron overload in renal failure patients: Changes since the introduction of erythropoietin therapy. Kidney Int Suppl 69:S35-S43, 1999
34. US Renal Data System: US Department of Public Health and Human Services, Public Health Service, Bethesda, MD, The National Institutes of Health, 2002
35. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD: Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 63:793-808, 2003
36. Fleischmann EH, Bower JD, Salahudeen AK: Risk factor paradox in hemodialysis: Better nutrition as a partial explanation. ASAIO J 47:74-81, 2001
37. Salahudeen AK: Obesity and survival on dialysis. Am J Kidney Dis 41:925-932, 2003
38. Barany P, Eriksson LC, Hultcrantz R, Pettersson E, Bergstrom J: Serum ferritin and tissue iron in anemic dialysis patients. Miner Electrolyte Metab 23:273-276, 1997
39. Kalantar-Zadeh K, Luft FC: Diagnosis of hemochromatosis. Ann Intern Med 131:311, 1999